Compounds and compositions as protease inhibitors

A compound of Formula (II):

• wherein:
• R2, R3, R4, R5 and R7 are hydrogen;
• R9 represents benzyloxymethyl, benzylsulfanylethyl, benzylsulfanylmethyl, benzylsulfinylmethyl, phenoxyethyl, pyridylsulfanylethyl, or phenylsulfanylethyl, wherein within R9 the aromatic ring may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, cyano, halo, halo-substituted (C1-4)alkyl, nitro, —X4NR12R12, —X4OR12, —X4C(O)R12, —X4C(O)OR12 and —X4SR12, wherein X4 is a bond or (C1-6)allkylene;
• and R12 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl;
• and
• R11 is —X4X5R18, wherein X4 is —C(O)—, X5 is a bond and R18 is (i) (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C1-6)alkyl or hetero(C5-12)aryl(C0-6)alkyl or (ii) phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl, wherein said phenyl or heteroaryl is substituted by —X9OR24, —X9C(O)R24, —X9C(O)OR24, —X9C(O)NR24R25, —X9NR24R25, —X9NR25C(O)R24, —X9NR25C(O)OR24, —X9NR25C(O)NR24R25 or —X9NR25C(NR25)NR24R25, wherein X9 is a bond or (C1-6)alkylene, R24 is phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl and R25 is hydrogen or (C1-6)alkyl, wherein within R11 any aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (C1-6)alkyl, halo, halo-substituted (C1-4)alkyl, —OR12, —X3SR12, —C(O)OR12 and —X3NR12C(O)OR12 wherein X3 is a bond or (C1-6)alkylene and R12 is hydrogen or (C1-6)alkyl;
• and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers;
• and the pharmaceutically acceptable salts thereof.

A method of treating a disease in an animal in which cathepsin S activity contributes to the pathology and/or symptomatology of the disease, which method comprising administering to the animal a therapeutically effective amount of a compound of Formula (I):

• in which:
• R1 is a group of Formula (a):
• wherein:
• X1 is —C(O)— or —CH2S(O)2—;
• R5 is hydrogen;
• R7 is hydrogen;
• R9 is (i) (C1-6)alkyl substituted with —OR14 or —SR14, wherein R14 is (C3-6)cycloalkyl(C0-6)alkyl, phenyl(C0-6)alkyl, biphenylyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl;
• wherein within R9 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, —X3NR12R12, —X3NR12C(O)OR12, —X3NR12C(O)NR12R12, —X3NR12C(NR12)NR12R12, —X3OR12, —X3SR12, —X3C(O)OR12, —X3C(O)NR12R12, —X3S(O)2NR12R12, —X3P(O)(OR3)OR12, —X3OP(O)(OR3)OR12, —X3OC(O)R13, —X3OC(O)R13, —X3NR12C(O)R13, —X3S(O)R13, —X3S(O)2R13 and —X3C(O)R13, wherein X3 is a bond or (C1-6)alkylene, R12 at each occurrence independently is hydrogen, (C1-3)alkyl or halo-substituted (C1-3)alkyl and R13 is (C1-3)alkyl or halo-substituted (C1-3)alkyl;
• and
• R11 is —X4X5R18, wherein X4 is —C(O)—, X5 is a bond and R18 is (i) (C3-12)cycloalkyl(C0-6)alkyl, hetero(C3-12)cycloalkyl(C0-6)alkyl, (C6-12)aryl(C0-6)alkyl or hetero(C5-12)aryl(C0-6)alkyl or (ii) phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl, wherein said phenyl or heteroaryl is substituted by —X9OR24, —X9C(O)R24, —X9C(O)OR24, —X9C(O)NR24R25, —X9NR24R25, —X9NR25C(O)R24, —X9NR25C(O)OR24, —X9NR25C(O)NR24R25 or —X9NR25C(NR25)NR24R25, wherein X9 is a bond or (C1-6)alkylene, R24 is phenyl(C0-6)alkyl or hetero(C5-6)aryl(C0-6)alkyl and R25 is hydrogen or (C1-6)alkyl, wherein within R11 any aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (C1-6)alkyl, halo, halo-substituted (C1-4)alkyl, —OR12, —X3SR12, —C(O)OR12 and —X3NR12C(O)OR12 wherein X3 is a bond or (C1-6)alkylene and R12 is hydrogen or (C1-6)alkyl;
• and
• R2 is hydrogen;
• and
• R3 and R4 are both hydrogen;
• and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers;
• and the pharmaceutically acceptable salts thereof.